Steven Cohen Immunocore Holdings PLC Transaction History

Point72 Asset Management, L.P.

$51 Billion
Q3 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 535,831 shares of IMCR stock, worth $19.3 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

535,831

Previous 820,425 34.69%

Holding current value

$19.3 Million

Previous $25.7 Million 24.39%

% of portfolio

0.04%

Previous 0.06%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$31.87 - $37.2 $9.07 Million - $10.6 Million	-284,594 Reduced 34.69%	535,831 $19.5 Million
Q2 2025 Aug 14, 2025	BUY	$24.53 - $38.65 $4.71 Million - $7.43 Million	192,133 Added 30.58%	820,425 $25.7 Million
Q1 2025 May 15, 2025	BUY	$28.21 - $33.0 $6.35 Million - $7.42 Million	224,988 Added 55.79%	628,292 $18.6 Million
Q4 2024 Feb 14, 2025	BUY	$28.14 - $34.69 $11.3 Million - $14 Million	403,304 New	403,304 $11.9 Million
Q2 2022 Aug 15, 2022	SELL	$25.46 - $37.72 $10.4 Million - $15.4 Million	-407,058 Closed	0 $0

Q1 2022 May 16, 2022	BUY	$18.94 - $34.29 $7.47 Million - $13.5 Million	394,658 Added 3182.73%	407,058 $12.2 Million
Q4 2021 Feb 14, 2022	SELL	$27.58 - $40.0 $3.77 Million - $5.46 Million	-136,600 Reduced 91.68%	12,400 $425,000
Q3 2021 Nov 15, 2021	BUY	$27.98 - $40.0 $2.13 Million - $3.04 Million	76,100 Added 104.39%	149,000 $5.52 Million
Q2 2021 Aug 16, 2021	BUY	$32.22 - $41.5 $2.35 Million - $3.03 Million	72,900 New	72,900 $2.85 Million

Others Institutions Holding IMCR

# of Institutions

146

Shares Held

46.9M

Call Options Held

325K

Put Options Held

1.74M

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.58B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account